Ignite Creation Date:
2025-12-24 @ 7:34 PM
Ignite Modification Date:
2026-01-01 @ 7:59 AM
Study NCT ID:
NCT05973903
Status:
WITHDRAWN
Last Update Posted:
2024-12-04
First Post:
2023-07-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Sponsor:
Tel Aviv Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-01
Start Date Type:
ACTUAL
Primary Completion Date:
2026-10-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-10-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-07-20
First Submit QC Date:
None
Study First Post Date:
2023-08-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-12-01
Last Update Post Date:
2024-12-04
Last Update Post Date Type:
ACTUAL